Thromb Haemost 2007; 97(06): 914-921
DOI: 10.1160/TH07-01-0034
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

International Registry on Factor XIII Deficiency: A basis formed mostly on European data

Authors

  • Vytautas Ivaskevicius

    1   Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
  • Rainer Seitz

    2   Paul-Ehrlich-Institute, Langen, Germany
  • Hans P. Kohler

    3   Laboratory for Thrombosis Research, Department of Clinical Research, Inselspital, University Hospital of Bern, Bern, Switzerland
  • Verena Schroeder

    3   Laboratory for Thrombosis Research, Department of Clinical Research, Inselspital, University Hospital of Bern, Bern, Switzerland
  • Laszlo Muszbek

    4   Clinical Research Center, Haemostasis, Thrombosis and Vascular Biology Research Group of the Hungarian Academy of Sciences, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
  • Robert A. S. Ariens

    5   Academic Unit of Molecular Vascular Medicine, General Infirmary, Leeds, United Kingdom
  • Erhard Seifried

    6   Institute for Transfusion Medicine and Immunohaematology, Red Cross Blood Donor Service Baden-Wuerttemberg- Hessen, Frankfurt, Germany
  • Johannes Oldenburg

    1   Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
    7   The Study Group*
  • and The Study Group
Weitere Informationen

Publikationsverlauf

Received 19. Januar 2007

Accepted after revision 06. März 2007

Publikationsdatum:
27. November 2017 (online)

Preview

Summary

FXIII deficiency is known as one of the rarest blood coagulation disorders. In this study, the phenotypic and in part genotypic data of 104 FXIII-deficient patients recorded from 1993 – 2005 are presented. The most common bleeding symptoms were subcutaneous bleeding (57%) followed by delayed umbilical cord bleeding (56%), muscle hematoma (49%), hemorrhage after surgery (40%), hemarthrosis (36%), and intracerebral bleeding (34%). Prophylactic treatment was initiated in about 70% of all patients. FXIII-B subunit-deficient patients had a milder phenotype than patients with FXIII-A subunit deficiency. The most frequent mutation affecting the F13A gene was a splice site mutation in intron 5 (IVS5–1G>A). This mutation was found in eight (17%) of 46 analyzed families. The haplotype analysis of patients carrying the IVS5–1A allele was consistent with a founder effect. The international registry (http://www.f13-database.de) will provide clinicians and scientists working on FXIII deficiency with a helpful tool to improve patient care and direct future studies towards better understanding and treatment of the disease.

* A list of the Study Group members can be found in the appendix.